Compare BioNano Genomics Inc (BNGO) vs GoPro Inc (GPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs GoPro Inc — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while GoPro Inc trades at $0.7 (market cap $120.72M). The key difference: GoPro Inc is far larger — about 9.1× BioNano Genomics Inc's market cap. Which is the better fit depends on your goals.
| BNGO | GPRO | |
|---|---|---|
Market Cap | $13.20M | $120.72M |
Sector | Health | Technology |
52-Week High | $4.92 | $2.88 |
52-Week Low | $1.09 | $0.64 |
Enterprise Value | $15.81M | $168.66M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
GoPro (GPRO) trades at $0.711, down 6.79% on the day, reflecting persistent operational challenges and negative investor sentiment. The stock exhibits a bearish technical outlook with consecutive earnings misses, declining revenue from $1.1B in 2022 to $652M in 2025, and negative net income margins. Recent news highlights a strategic review for potential sale or merger amid financial distress, including a $20M financing injection from CEO Nicholas Woodman in July 2026 to bolster liquidity.
The investment outlook remains highly speculative, with opportunities tied to a potential strategic transaction offering upside, but severe risks include going-concern warnings, cash burn, and competitive pressures. Analyst consensus is cautious, with only 21% buy ratings, emphasizing the binary nature of outcomes based on the company's ability to secure a lifeline or execute a turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
